Pharmaceutical

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate the availability of more affordable alternatives to brand-name drugs, including blockbusters like Novo Nordisk A/S’s (NYSE:NVO) Ozempic...

Intra-Cellular Therapies Inc (NASDAQ:ITCI) unveiled on Tuesday topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).  Topline results from the second Phase 3 study, Study 502, are anticipated...

Moderna Inc (NASDAQ:MRNA) will be reporting its fourth-quarter earnings on Feb. 22. Wall Street expects a negative 99 cents in EPS and $2.53 billion in revenues as the company reports before market hours. Moderna is renowned for its development of mRNA-based vaccines, including the COVID-19 vaccine...

CEOs of Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) defended the high prices of their drugs as they were grilled by the Senate Health Committee, led by Senator Bernie Sanders who submitted a report blasting the extravagant cost of three drugs. "Merck...

With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never seems to win. Moderna ended 2023 by...

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.  Along with lovo-cel, Vertex Pharmaceuticals Inc/...

Industry giant Morgan Stanley (NYSE:MS) is shaking up its model for income-focused investors, indicating a strategic move towards robust and resilient players. The multinational investment bank told investors Thursday that it added new positions and adjusted weights in its dividend portfolio. What...

Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities. The Teva Pharmaceutical Industries Analyst: Jason Gerberry upgraded the rating for Teva...

Johnson & Johnson (NYSE: JNJ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible...

Moderna Inc (NASDAQ: MRNA) announced a double dose of positive tidings Monday, but the stock is still wallowing in the red amid a sell-off seen across vaccine stocks. Moderna Augments Supply Deal With Canada: Cambridge, Massachusetts-based Moderna announced a revised supply agreement...

It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: ABBV), Cerity Partners' Jim Lebenthal shared Wednesday on CNBC's "Fast Money Halftime Report." Lebenthal told CNBC that he is slowly building the pharmaceutical portion of his...

On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state, Reuters reports.  J&J will not face the jury trial scheduled to begin on Tuesday on Long Island with...

A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning. The SPAC Deal: Roviant Sciences announced a SPAC deal with Montes Archimedes Acquisition Corp (NASDAQ: MAAC). The deal values the...

Shares of generic and specialty medicines maker Teva Pharmaceutical Industries (NYSE: TEVA) fell more than 9 percent Monday morning in reaction to a lawsuit filed by 44 states. What Happened Teva, along with other global drug companies, is accused of conspiring to inflate the prices of their...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP), a clinical-stage pharmaceutical company that focuses on therapies to treat inflammatory and fibrotic diseases, gained more than 5 percent Thursday after the company announced a new strategic collaboration. What Happened Corbus said...